Nimenrix® (Meningococcal group ACW₁₃₅Y conjugate vaccine)
What is Nimenrix® (meningococcal group A, C, W-135 and Y conjugate vaccine) and what is it used for?
Nimenrix is a conjugate vaccine that helps to provide protection against invasive disease caused by the bacteria Neisseria meningitidis types A, C, W-135 and Y. Invasive disease occurs when there is systemic spread of bacterium throughout the body causing serious infections such as septicaemia (blood infection) and meningitis (infection of the membranes around the brain and spinal chord).
Nimenrix may be given to adults, adolescents, children and infants over the age of 6 weeks.
Nimenrix will only protect against infections caused by the bacteria Neisseria meningitidis types A, C, W-135 and Y. As with all vaccines, Nimenrix may not protect everyone who is fully vaccinated.
When should the vaccine be administered?
Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks and should be used in accordance with official available recommendations.
The medicine can only be obtained with a prescription.
Reference information
- The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in London. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See what guidance they offer about Nimenrix.
- If you would like to see the Patient Information Leaflet or Summary of Product Characteristics for Nimenrix these can be found at the electronic Medicines Compendium (eMC).
- View the national immunisation schedule
Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professionals for specific, health-related advice and support.
If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse.. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.